公开(公告)号：WO2004047771A2

公开(公告)日：2004-06-10

申请号：PCT/US2003/038175

申请日：2003-11-25

Applicant: ATTENUON, LLC.

Inventor： ALLAN, Amy, L. ,  DONATE, Fernando ,  HOPKINS, Stephanie, A. ,  GLADSTONE, Patricia, L. ,  MAZAR, Andrew ,  O'HARE, Sean, M. ,  PARRY, Graham ,  PLUNKETT, Marian, L. ,  TERNANSKY, Robert, J. ,  YOON, Won, Hyung

IPC: A61K

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K47/62

Abstract: The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell , pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

Abstract translation: 本发明一般涉及抑制血管发生，细胞迁移，细胞侵袭和细胞增殖的肽，抑制血管生成，抑制血管生成，细胞迁移，细胞侵袭和细胞的方法，这些肽的药物组合物以及使用这些肽的方法和 这些肽的药物组合物用于治疗与异常血管形成相关的疾病。

公开(公告)号：WO2004009034A2

公开(公告)日：2004-01-29

申请号：PCT/US2003/023031

申请日：2003-07-22

Applicant: ATTENUON, LLC.

Inventor： TERNANSKY, Robert, J. ,  MAZAR, Andrew ,  GLADSTONE, Patricia, L. ,  COUCOUVANIS, Dimitri ,  ALLAN, Amy, L. ,  O'HARE, Sean, M. ,  PRICE , Mellissa, L., P. ,  PIRIE-SHEPHERD, Steven, Robert ,  DONATE, Fernando

IPC: A61K

CPC classification number: C07D213/20 ,  C07C211/62 ,  C07C211/63 ,  C07C211/64 ,  C07C215/40 ,  C07C217/08 ,  C07C219/06 ,  C07C229/60 ,  C07C317/28 ,  C07D213/53 ,  C07D233/54 ,  C07D295/037 ,  C07D295/088

Abstract: The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-κB dysregulation and methods of using pharmaceutical compositions of thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-κB dysregulation.

Abstract translation: 本发明提供了新型硫代钼酸盐衍生物，制备新型硫代钼酸盐衍生物的方法，新型硫代钼酸盐衍生物的药物组合物，使用新型硫代钼酸盐衍生物治疗异常血管形成相关疾病的方法，铜代谢障碍，神经变性疾病 ，肥胖症或NF-κB调节异常以及使用硫代钼酸盐衍生物的药物组合物治疗与异常血管形成，铜代谢紊乱，神经变性疾病，肥胖症或NF-κB失调有关的疾病的方法。

公开(公告)号：WO2004063213A2

公开(公告)日：2004-07-29

申请号：PCT/US2003/037895

申请日：2003-11-25

Applicant: ATTENUON, LLC

Inventor： ALLAN, Amy, L. ,  YOON, Won, Hyung ,  GLADSTONE, Patricia, L. ,  TERNANSKY, Robert, J. ,  PARRY, Graham ,  DONATE, Fernando ,  MAZAR, Andrew

IPC: C07K

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K47/62

Abstract: The present invention relates generally to peptide analogs of Ac-PHSCN-NH 2 which target tumor and endothelial cells and have anti-tumor, anti-angiogenic and anti-metasastic activity, methods of making these peptides, compositions thereof and methods of using these peptides and pharmaceutical compositions thereof to treat, prevent and detect diseases characterized by tumor growth, metastasis and angiogenesis. The peptide analogs may serve, inter alia , as carriers of radioactivity, PET-active compounds, toxins, fluorescent molecules and PEG molecules.

Abstract translation: 本发明一般涉及靶向肿瘤和内皮细胞并具有抗肿瘤，抗血管生成和抗代谢活性的Ac-PHSCN-NH2的肽类似物，制备这些肽的方法，其组合物和使用这些肽的方法和 用于治疗，预防和检测以肿瘤生长，转移和血管发生为特征的疾病的药物组合物。 肽类似物尤其可以用作放射性载体，PET活性化合物，毒素，荧光分子和PEG分子。

公开(公告)号：WO2004024877A2

公开(公告)日：2004-03-25

申请号：PCT/US2003/028881

申请日：2003-09-15

Applicant: ATTENUON, LLC ,  DOÑATE, Fernando ,  MAZAR, Andrew

Inventor： DOÑATE, Fernando ,  MAZAR, Andrew

IPC: C12N

CPC classification number: A61K51/088 ,  A61K38/00 ,  A61K41/0095 ,  A61K49/0002 ,  C07K14/8139

Abstract: Human kininogen domain 3 (HK-D3) polypeptides and biologically active variants and derivatives of HK-D3 are anti-angiogenic. These molecules are used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic. Because of their anti-angiogenic potential, these molecules are useful in the treatment of cancer by inhibiting or reversing the growth of primary of metastatic tumors.

Abstract translation: 人激肽原结构域3（HK-D3）多肽和HK-D3的生物活性变体和衍生物是抗血管生成的。 这些分子用于抑制血管生成或治疗其中血管发生是致病性的疾病或病症。 由于其抗血管生成潜力，这些分子可用于通过抑制或逆转转移性肿瘤原发性生长来治疗癌症。